Navigation Links
Study finds warfarin underutilized in women
Date:12/13/2011

LEXINGTON, Ky. (Dec. 13, 2011) Dr. Rabab Mohsin, an internal medicine resident at the University of Kentucky, working with Dr. Alison Bailey of the University of Kentucky Gill Heart Institute, has discovered that the drug warfarin was underutilized in a large study group of women.

Working in conjunction with the Kentucky Women's Health Registry, Mohsin, Bailey and fellow investigators identified women who reported arrhythmia (irregular heartbeat) identification and treatment. Specifically, the investigators worked to determine whether prescription warfarin (an anti-coagulant known as a safe and effective treatment for atrial fibrillation) was being appropriately utilized among a population of Kentucky women with self-reported atrial fibrillation.

Survey data revealed that among the group of women who would be expected to be receiving warfarin, only 30 percent were receiving the drug. Notably, the research population was found to have a higher than average level of income and education as compared to other Kentucky women in their age group. Statistical analysis also revealed that older women were more likely to be taking warfarin (a mean age of 73.4 years was found for those with atrial fibrillation who were on warfarin, while the population with atrial fibrillation but without warfarin treatment had a mean age of 61.8).

Overall, Mohsin, Bailey and fellow investigators concluded that warfarin anticoagulation treatment for atrial fibrillation is underutilized in the group of Kentucky women studied, and that this underutilization is not attributable to economic or educational disparities.


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert

Page: 1

Related medicine news :

1. RI Hospital receives $1.5 million grant to study treatments for body dysmorphic disorder
2. Study explores mens ability to manage fear in ways that allow them to exhibit confidence
3. JDRF-funded study seeks to reduce cardiovascular risk
4. Study Questions Use of MRI Before Back-Pain Injections
5. ADHD Drugs Dont Raise Risk of Heart Problems: Study
6. Snakes Make Your Skin Crawl? Study Suggests Why
7. Study of 2 sisters sheds light on lymphoma evolution
8. Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal
9. Patient isolation associated with hospital delirium: study
10. Ruxolinitib better at reducing myelofibrosis symptoms, study shows
11. Study favors as-needed treatment over maintenance therapy for patients with follicular lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 ... ... interoperability, today announced that the company will provide alerting technology to Central ... been recently awarded $1.7 million in federal funds as the sole sub-recipient ...
(Date:12/5/2016)... ... , ... U.S. Apple Association (USApple) begins the holiday giving season by donating ... for Education: Buy an Apple, Help a Student fundraising campaign. , ... home to their families; solar technology to efficiently process compost; and iPads to enhance ...
(Date:12/5/2016)... ... , ... “Life Will Never Be The Same” is a fictional tale about ... Be The Same” is the creation of published author, Kim T. Briggs, a self-described ... degree in Christian religion and philosophy from Judson University in Elgin, Illinois. Having written ...
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves come ... buy neoprene knee sleeves for lifting and any sport that requires knee ... two main aspects to provide a higher quality knee sleeve performance. Firstly it is ...
(Date:12/5/2016)... ... December 05, 2016 , ... Z-Medica, LLC, a leading developer ... The American College of Surgeons (ACS) to provide basic bleeding control instructor training ... Basic” course is a pilot program that fulfills the intent of the White ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the ... SelG1), an anti-P-selectin antibody, reduced the median annual rate ... to placebo (1.63 vs 2.98, p=0.010) in patients with ... that the data are being featured in the official ... of Hematology (ASH) Annual Meeting and presented during the ...
(Date:12/2/2016)... SPRING, Md. , Dec. 2, 2016 ... new indication for Jardiance (empagliflozin) to reduce the risk ... diabetes mellitus and cardiovascular disease. "Cardiovascular ... with type 2 diabetes mellitus," said Jean-Marc Guettier ... and Endocrinology Products in FDA,s Center for Drug Evaluation ...
Breaking Medicine Technology: